This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug, changing your diet or commencing any course of treatment.
Very important. A change in your diet, medicine, or dosage may be necessary. Promptly consult your doctor or pharmacist.
How the interaction occurs:
Grapefruit juice may increase the amount of maraviroc in your blood.
What might happen:
When maraviroc is taken with grapefruit juice, the grapefruit juice may cause maraviroc to build up in your body. This increased amount of maraviroc may increase your risk for maraviroc associated adverse drug effects, including damage to your liver.
What you should do about this interaction:
While you are taking this medicine, you should avoid eating grapefruit or drinking grapefruit juice. You may choose an alternative citrus beverage (such as orange juice). In the event that you are instructed by a healthcare professional (e.g., doctor, pharmacist, or dietitian) to eat grapefruit or drink grapefruit juice you should discuss with your doctor the effects of grapefruit on the blood levels of this medicine. These effects can occur even if grapefruit is not consumed at the same time of the maraviroc dose. This interaction may occur at any time in your treatment with maraviroc if grapefruit or grapefruit juice is consumed.Stop taking maraviroc and call your doctor right away if you develop yellow eyes or skin, dark urine, vomiting, or abdominal pain. Let your doctor know right away if you develop nausea, fever, flu-like symptoms, or fatigue, but continue taking your maraviroc. Let your doctor know if you have any kidney or liver problems, which may make the interaction more severeYour healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Selzentry (maraviroc) US prescribing information. Pfizer Inc. May, 2010.
2.Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008 Apr;65 Suppl 1:27-37.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.